The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|1|3|207-215

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.1, Iss.3, 2006-09, pp. : 207-215

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System

By  

Oncology Research and Treatment, Vol. 33, Iss. 4, 2010-03 ,pp. : 155-166

Karger

Access to resources Recommend Favorite

Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials

By  

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 14-21

Karger

Access to resources Recommend Favorite

The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial

By  

Oncology, Vol. 81, Iss. 5-6, 2011-12 ,pp. : 298-305

Karger

Access to resources Recommend Favorite

The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population

By  

Oncology, Vol. 86, Iss. 1, 2013-12 ,pp. : 16-21

Karger

Access to resources Recommend Favorite

Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2++ metastatic breast cancer with letrozole alone or in combination with lapatinib

By Sherrill Beth   Sherif Bintu   Amonkar Mayur M.   Maltzman Julie   O’Rourke Lisa   Johnston Stephen  

Current Medical Research and Opinion, Vol. 27, Iss. 12, 2011-12 ,pp. : 2245-2252

Informa Healthcare

Access to resources Recommend Favorite